Synthesis of cell attachment proteins and cytokines, such as osteopontin (OPN), can promote tumor cell remodeling of the extracellular matrix into an environment that promotes tumor cell attachment and migration. We investigated the transcriptional regulation of OPN in the U-251MG and U-87MG human malignant astrocytoma cell lines. Deletion and mutagenesis analyses of the OPN promoter region identi®ed a proximal promoter element (724 to 794 relative to the transcription initiation site) that is essential for maintaining high levels of OPN expression in the tumor cells. This element, designated RE-1, consists of two cis-acting elements, RE-1a (755 to 786) and RE-1b (722 to 745), which act synergistically to regulate the activity of the OPN promoter. Gel shift assays using nuclear extracts of U-251MG cells demonstrated that RE-1a contains binding sites for transcription factors Sp1, the glucocorticoid receptor, and the E-box-binding factors, whereas RE-1b contains a binding site for the octamer motif-binding protein (OCT-1/OCT-2). Inclusion of antibodies directed toward Myc and OCT-1 in the gel shift assays indicated that Myc and OCT-1 participate in forming DNAprotein complexes on the RE-1a and RE-1b elements, respectively. Our results identify two previously unrecognized elements in the OPN promoter that act synergistically to promote upregulation of OPN synthesis by tumor cells but are regulated by dierent transcription factors. Oncogene (2000) 19, 5801 ± 5809.
Introduction
Accumulating evidence indicates that tumors can actively promote their own expansion by manipulating their microenvironment. We are particularly interested in the ability of malignant astrocytomas to remodel their extracellular matrix by secreting matrix proteins, and proteins that promote cell attachment (Gladson and Cheresh, 1991; Gladson et al., 1995; PijuanThompson et al., 1999) . The signi®cant mortality associated with malignant astrocytomas is directly attributable to the invasion of the normal brain by the tumor (Russell and Rubenstein, 1989) , which requires integrin-mediated attachment and migration of the tumor cells to the extracellular matrix. Although migration can occur on the existing matrix of the normal brain (reviewed in Gladson, 1999) , the tumor cells can actively remodel their extracellular matrix through the synthesis of matrix proteins and cell attachment proteins that promote cell attachment and migration. Malignant astrocytoma cells in vivo exhibit upregulation of at least two such proteins, vitronectin (Gladson and Cheresh, 1991; Gladson et al., 1995) and osteopontin (OPN) (Saitoh et al., 1995) . OPN is not expressed in the normal matrix of most tissues, other than mineralized tissues, but it is synthesized by cells in response to various stimuli, and thus is considered to be a cytokine (Denhardt and Noda, 1998) . OPN also promotes cell attachment and migration through its recognition as a ligand by several cell adhesion receptors, e.g., integrins a v b 3 and a v b 5 ; thus, OPN also is considered to be a cell attachment protein (Liaw et al., 1995; Gladson et al., 2000) . Integrins a v b 3 and a v b 5 are upregulated on malignant astrocytoma cells in vivo (Gladson et al., 1995) , therefore, OPN could potentially promote malignant astrocytoma cell attachment and migration.
The elevated levels of OPN in a wide variety of malignant cells (Denhardt and Guo, 1993; Brown et al., 1994) suggests that it may play a key role in tumorigenesis; indeed, OPN was originally called transformation-associated protein. Several lines of evidence support this concept. The concentration of OPN is substantially elevated in the blood of patients with metastatic cancer (Senger et al., 1998) . Increased expression of OPN is associated with ras transformation of NIH3T3 ®broblasts (Chambers et al., 1992) , and the ras-transformed ®broblasts require OPN for their growth (Gardner et al., 1994; Su et al., 1995) . In murine cells, the v-src transforming oncogene stimulates OPN expression (Tezuka et al., 1996) and cells homozygous for c-src disruption exhibit suppression of OPN synthesis (Chackalaparampil et al., 1996) . Finally, transformation of mouse epidermal cells by the tumor promoter, TPA, is associated with the induction of OPN (Smith and Denhardt, 1987; Chang and Prince, 1993) .
Although these studies implicate the regulation of OPN expression in the promotion of tumor cell proliferation and attachment, as well as migration, the mechanisms that regulate the expression of OPN are still only poorly understood. Expression of OPN is known to be in¯uenced by a number of dierent factors, including hormones, growth factors, tumor promoters, and oncogenes (Denhardt and Guo, 1993; Denhardt and Noda, 1998; Manji et al., 1998; Sato et al., 1998; Vanacker et al., 1998) . The regulation of OPN expression appears to be exerted largely at the level of transcription (Denhardt and Noda, 1998) and the OPN promoter region, speci®cally the 5' upstream sequence of the human OPN gene (up to base pair 7250), is highly conserved among the human, murine, and porcine genes (Hijiya et al., 1994) . In osteosarcoma cells, transforming growth factor-b has been shown to stimulate OPN transcription as well as protein expression (Noda et al., 1988) . Similarly, OPN mRNA is increased in ras-transformed NIH3T3 cells in proportion to the level of Ras expression (Chambers et al., 1992) . The transactivating eect of ras on OPN expression has been attributed to a DNA regulatory element in the OPN promoter (Guo et al., 1995) and the v-src transforming oncogene has been shown to stimulate mouse OPN expression through a CCAAT box-like sequence in the OPN promoter (Tezuka et al., 1996) .
A previous study of the human OPN promoter demonstrated binding of nuclear proteins to several DNA elements within a proximal sequence of the promoter (Hijiya et al., 1994) . Here, we report the identi®cation of two regulatory sequences in the proximal region of the promoter that are essential for OPN expression in astrocytic cells and identify transcription factors that bind to these sequences speci®cally. These two sequences appear to function synergistically in maintaining the high level of OPN expression in malignant astrocytic cells. Using mutagenesis analysis, we also located elements within these two sequences that are important for the function of the entire sequence.
Results

Deletion analysis of an OPN promoter sequence
Sequential 5'-deletion mutant constructs were prepared as described by Hijiya et al. (1994) . A region of the promotor sequence shown to confer ecient transcription of the OPN gene and the 5' deletion sequences ( Figure 1) were cloned into the pGLG2-basic reporter plasmid, and the luciferase activity was assayed in transfected primary rat astrocytes and two representative malignant astrocytoma cell lines (U-251MG and U-87MG).
In both the human astrocytoma cell lines and the normal rat astrocytes, deletion of a 71 bp fragment, from 794 to 724, resulted in a dramatic loss of OPN promoter activity (490% reduction) (Figure 1a ,b, respectively), pinpointing this proximal region (794 to 724) of the OPN promoter as the region that contains the essential regulatory sites for basal expression of OPN transcription. We named this proximal 71 bp fragment RE-1 and focused our studies on this region. The analysis of the eects of the sequential deletion mutants revealed, however, two other points of interest. In the primary rat astrocytes, deletion of the sequence between 7439 and 794 resulted in a 50% reduction in the promoter activity (Figure 1b) , whereas sequential deletion from 71206 to 794 in the malignant human astrocytoma cell lines had either no eect or only a minimal eect on the promoter activity ( Figure 1a) . Also, deletion of the sequence between 7439 and 7124 caused a slight increase (*20%) in OPN transcription in the U-251MG cells, suggesting that a negative regulatory element could be present in the sequence between 7439 and 7124.
To determine the functional importance of the RE-1 sequence (794 to 724) in OPN transcription, we placed this fragment upstream of the herpes simplex TK promoter in the pT81Luc plasmid and evaluated luciferase activity in three human malignant astrocytoma cell lines (U-251MG, U-87MG, and U-373MG). In all three cell lines, the expression of the luciferase reporter gene was increased signi®cantly (Figure 1c ). This ability of the RE-1 sequence to activate transcription from a heterologous minimal promoter indicates that RE-1 possesses sucient . The names of the 5' deletion constructs indicate the OPN promoter sequences that were placed upstream of the luciferase gene. Luciferase activities were assayed 30 h after transfection, with that of the 1.3 kb promoter construct (OPN71206/+90) standardized to 100%. Luciferase activity from the wild type promoter ranged between 10 000 and 20 000 light units, while the background activity of the assay was between 100 and 200 light units. The relative position of RE-1 is indicated. (c) RE-1 is able to activate transcription from a heterologous promoter. The RE-1 OPN promoter fragment was cloned upstream of the herpes simplex virus TK promoter in the pT81Luc plasmid to create pRE-1-TK-Luc. pT81Luc and pRE-1-TK-Luc were transiently transfected into U-251MG, U-87MG, and U-373MG cells. Luciferase activities were assayed 25 h after transfection, with that of the pT81Luc construct standardized to 100%. These experiments were repeated twice and the results analysed and presented as the mean+ s.e.mean regulatory information to regulate transcription independently, and that it acts like a transcriptional enhancer in the OPN promoter.
Mutagenesis analysis of the RE-1 region
To further de®ne the RE-1 element, we introduced a series of site-directed mutations into the RE-1 sequence (Figure 2a ), subcloned these upstream of the luciferase gene and transiently transfected U-251MG cells. Four mutations within the sequence between 755 and 786 (755/762M, 763/770M, 771/778M, and 779/ 786M), and three mutations within the sequence between 722 and 745 (722/729M, 730/737M, and 738/745M) resulted in signi®cant losses of promoter activity that ranged from 25% to 40% (Figure 2a) . A mutation between these two sequences (746/753M) had only a minimal eect on transcription (*20% decrease). These results suggest that RE-1 contains two cis-acting elements, 755 to 786, which we designated RE-1a, and 722 to 745, which we designated RE-1b, that are necessary for the transcription of OPN.
To con®rm the functional importance of the RE-1a and RE-1b elements, we performed internal deletion analysis of the OPN promoter region (Figure 2b ). In U-251MG and U-87MG cells, deletion of the RE-1a (D755/786) or the RE-1b (D722/745) elements from RE-1 caused a drastic reduction in the promoter activity. The simultaneous deletion of both RE-1a and RE-1b, as indicated by the mutant construct D722/ 786, resulted in an even greater loss of the promoter activity, suggesting that these elements act in an additive or a synergistic manner to regulate the OPN promoter.
Identification of transcription factor(s) binding to the RE-1a and RE-1b elements by gel shift analysis
RE-1a
The potential target(s) for transcription factors in RE1a were identi®ed in gel shift assays using an 32 Plabeled RE-1a oligonucleotide substrate and nuclear extracts from the U-251MG cells (Figure 3a) . The U-251MG cells were utilized for all gel shift assays, as these cells are most representative of human malignant astrocytoma tumors and are tumorigenic in xenograft models with an invading tumor margin (Gladson et al., Figure 2 Mutagenesis analysis of the RE-1 element. (a) Oligonucleotide-directed mutations were introduced into the 0.5 kb OPN promoter (OPN7439/+90) and the mutant promoter constructs were cloned upstream of the luciferase gene. Mutant promoters are designated by the 5' and 3' positions of the mutated or deleted sequences. The relative positions of the mutations are shown on the left. The constructs were transfected into U-251MG cells and luciferase activities were assayed between 30 and 48 h after transfection. Relative promoter activities are diagramed on the right with that of the wild type OPN7439/+90 promoter standardized to 100%. (b) Same as (a), except that the constructs were transfected into the U-251MG and U-87MG cells, and the promoter activities of internal deletion mutants lacking RE-1a, RE-1b, or both were analysed. These experiments were repeated twice and the results analysed and presented as the mean+s.e.mean Figure 3 Gel shift assays using RE-1a or RE-1b element as probes. (a) Double-stranded oligonucleotides containing either RE-1a (lanes 1 ± 7) or RE-1b (lanes 8 ± 11) were radiolabeled and incubated with U-251MG nuclear extracts. Where indicated, a 100-fold excess of the competitor oligonucleotides was also added. The reaction was resolved on a nondenaturing polyacrylamide gel. The DNA-protein complexes resulting from sequence-speci®c transcription factor binding are indicated. Short arrowheads indicate nonspeci®c protein-DNA complexes. The free, unbound probe is indicated by an arrow. Similar results were found with three preprarations of nuclear extracts. . Proteins in the nuclear extracts of U-251MG cells formed complexes with the labeled RE-1a oligonucleotide that resolved as four bands on the gel ( Figure 3a , lane 1). We designated these bands as I, II, III, and IV. The formation of the RE-1a-protein complexes was unaected by addition of excess irrelevant oligonucleotide (data not shown); whereas, a 100-fold excess of the corresponding unlabeled oligonucleotide competitively inhibited the complex formation and all four bands were eliminated ( Figure  3a , lane 2). Thus, bands I, II, III, and IV result from sequence-speci®c binding of nuclear proteins to RE-1a. It was noted, however, that the intensity of Band IV varied among dierent nuclear extracts preparations of the same cell line (see Figure 4 , lane 2, and Figure 5 , lane 1).
Database analysis of the RE-1a element for known consensus sequences indicated the presence of potential binding sites for several transcription factors including the proto-oncoprotein, c-Myc; a site for the glucocorticoid receptor (GR); a site for Sp1; and three sites for the upstream stimulatory factor (USF) (Figure 3b ). To determine whether these transcription factors are involved in forming DNA-protein complexes with RE-1a, unlabeled oligonucleotides containing consensus binding sites for these transcription factors were used as competitors in the gel shift assays. As shown in Figure 3a , excess unlabeled Sp1 oligonucleotide completely inhibited the formation of the RE-1a complexes represented by bands I and III, but did not aect the formation of the complexes represented by bands II and IV (Figure 3a, lane 3) . As a doublet pattern is typical of Sp1/DNA interactions in gel shift assays, bands I and III most likely represent a DNAprotein complex containing Sp1. Excess transcription factor GRE competitively inhibited the DNA-protein complex represented by Band IV (Figure 3a , lane 5).
The exact identity of the transcription factor in the protein-DNA complex represented by band II remains unclear. In our experiments, both myc and E-box oligonucleotides were able to competitively inhibit the formation of the DNA-protein complex represented by RE-1a band II (Figure 3a , lanes 7 and 4, respectively). It has been reported that several transcription factors, including Myc and USF, are able to bind to the myc consensus sequence (Gregor et al., 1990; Li et al., 1994) and the myc and USF binding sites are typically referred to collectively as the E-box. The consensus element for USF-1 (a member of the USF family) also competitively inhibited the formation of the DNAprotein complex represented by the RE-1a band II (Figure 3a , lane 6). Given the fact that the core binding sequences for USF and Myc are strikingly similar, it is unclear at this point whether transcription factor(s), Myc, USF, or both, are bound by RE-1a.
RE-1b
Using a similar approach, we identi®ed the transcription factors that bind to the RE-1b element. In this case, incubation of the 32 P-labeled RE-1b oligonucleotide substrate with the nuclear protein extracts of U-251MG cells revealed the formation of complexes Figure 4 Antibody blocking assay of protein binding to the RE1a and RE-1b elements. Gel shift assay using the RE-1a (lanes 1 ± 5) or RE-1b (lanes 6 ± 10) probe and U-251MG nuclear extracts. Where indicated, a 100-fold molar excess of the unlabeled RE-1a (OPN751/796) or RE-1b (OPN719/750) oligonucleotide was added as competitor. An antibody directed toward Myc, OCT-1, or OCT-2 was also added as indicated Gel shift assay using RE-1a (lanes 1 ± 5) or RE-1b (lanes 6 ± 9) probe and U-251MG nuclear extracts. Where indicated, a 100-fold molar excess of the competitor oligonucleotide (including sequences #1 through #5 as indicated in (a) was added represented by three bands (Figure 3a, lane 8) . The banding pattern was distinct from that generated by the RE-1a probe and RE-1a and RE-1b did not compete with each other for protein binding, suggesting that dierent nuclear proteins bind to these elements (data not shown). We designated the bands associated with the complexes formed with the RE-1b oligonucleotide as A, B, and C. The complex formation was sequence-speci®c, as excess unlabeled probe competitively inhibited the formation of the DNAprotein complexes represented by the three bands (Figure 3a, lane 9) ; whereas, the addition of excess nonspeci®c oligonucleotide, Sp1, had no eect on the band pattern (Figure 3a, lane 10) . Database analysis of the RE-1b element for known consensus sequences indicated the presence of a potential site for binding of the octamer motif binding protein Oct-1/Oct-2 ( Figure  3b ). As the OCT-1 and OCT-2 consensus sequences are essentially the same, we performed gel shift assays using the OCT-1 consensus element as a competitor. Excess of this oligonucleotide completely inhibited the formation of the complexes represented by all three RE-1b bands (Figure 3a , lane 11), suggesting that OCT-1 or OCT-2, or both, speci®cally bind to the RE1b element. A band migrating between bands A and B and designated by an arrowhead in Figure 3 may represent a component with partial speci®city, as its intensity was reduced, but not eliminated, by the addition of either the unlabeled RE-1b or the OCT-1 oligonucleotide (Figure 3a , lanes 9 and 11, respectively).
Analysis of transcription factor binding to RE-1a and RE-1b elements by antibody supershift/blocking assays Analysis of Myc binding to RE-1a Increased Myc protein expression is a marker of the most malignant astrocytic tumors (Trent et al., 1986; Ehgelhard et al., 1989; Orian et al., 1992) . Therefore, we used a monoclonal antibody directed toward Myc in gel shift assays to investigate whether the myc transcription factor binds RE-1a (Figure 4) . The intensity of band II was reduced in a dose-dependent fashion (Figure 4 , lanes 4 and 5) but the band was not eliminated completely even on further increases in the antibody concentration (data not shown). These data indicate that Myc is involved in the formation of a transcription factor complex with RE-1a. A transcription factor(s) other than Myc may also participate in the formation of this complex, or the presence of Myc may facilitate the formation of the complex represented by band II.
Analysis of the binding of the OCT family of transcription factors to RE-1b
Rabbit polyclonal antibodies directed toward the OCT family of transcription factors were used to further characterize the binding of OCT-1 and OCT-2 to the RE-1b element. Anti-OCT-1 antibody completely blocked formation of the DNA-protein complex represented by band A, indicating that OCT-1 either binds to RE-1b, facilitates the binding of another transcription factor(s), or both (Figure 4, lane 9) . The anti-OCT-2 antibody and the OCT-1/OCT-2 consensus oligonucleotide reduced the intensity of the band migrating between bands A and B, denoted by an arrowhead in this Figure, suggesting that this band may have partial speci®city and that OCT-2 may bind to RE-1b. Interestingly, although an OCT-1/OCT-2 consensus oligonucleotide was able to completely inhibit the formation of the DNA-protein complex represented by RE-1b bands B and C (Figure 3a, lane  11) , both anti-OCT-1 and anti-OCT-2 antibodies failed to aect the intensity of these bands (Figure 4 , lanes 9 and 10, respectively). One possible interpretation is that another transcription factor(s) also binds to RE1b and participates in the complex formation represented by bands B and C. Taking into account that the oligonucleotide containing the OCT-1/OCT-2 binding sequence was able to block protein binding to RE-1b, these results indicate that another transcription factor(s) must recognize and speci®cally bind to a sequence that is identical to or closely resembles the consensus OCT-1/OCT-2 sequence.
Location of the binding sequences for transcription factors within RE-1a and RE-1b RE-1a RE-1a contains multiple potential sites for transcription factors (Figure 3b ). To pinpoint the corresponding binding site for each transcription factor, we constructed a series of deletion variants of RE-1a ( Figure  5a ) and used these as competitors in gel shift assays (Figure 5b ). The ®rst oligonucleotide (oligonucleotide #1) contained the putative GRE and two USF sites of RE-1a. This deletion variant blocked protein binding to the E-box site in a manner similar to that observed on competitive inhibition with the complete RE-1a oligonucleotide (Figure 5b, lane 3) . Thus, either of the two USF sites contained in this oligonucleotide, or both, is sucient for protein binding to the E-box sequence. Moreover, these data indicate that the other USF site, which was not included, and the c-Myc site, which was only partially included, in this deletion variant, are not necessary for the E-box binding. Finally, although this deletion variant contained the entire potential GRE site, it only partially aected the appearance of band IV. This may indicate that other anking nucleotides, especially those 5' to the GRE site, are necessary for strong binding of GR. Similar results were found with the deletion variant oligonucleotide #2 (Figure 5b, lane 4) . The third deletion variant used, oligonucleotide #3, contained the ®rst USF site in its entirety but only a portion of the second USF site. This oligonucleotide competed poorly for protein binding to the E-box site (Figure 5b , lane 5), suggesting that either the second USF site is the bona ®de E-box sequence or both USF sites are needed for transcription factor binding. This oligonucleotide contained only a partial GRE site, and, as anticipated, it failed to block the formation of the GRE complex.
In summary, the two distal USF elements contained in oligonucleotide #1 are sucient for binding of the E-box factor(s). However, the second USF element from the 5' end is necessary for the formation or maintenance of the E-box complex. The GRE indicated in Figure 5a is likely the core GR binding sequence, while nucleotides¯anking this core are required for strong binding of GR to the DNA. The Sp1 element in RE-1a (indicated in Figure 5a ) is required for Sp1 binding to the RE-1a.
RE-1b
RE-1b has a 23 bp 5'¯anking sequence containing the potential OCT-1/OCT-2 site, and it could also contain unidenti®ed binding sequences for transcription factors (Figure 3b) . To pinpoint the corresponding binding site for each transcription factor, we constructed a series of deletion variants of RE-1b (Figure 5a ) and these sequences were used as competitors in gel shift assays (Figure 5b ). Oligonucleotide #4 contained the complete OCT-1/OCT-2 sequence and six¯anking nucleotides. This deletion variant was able to inhibit the binding of the OCT-1 band (band A) and band C to the same extent (Figure 5b, lane 8) as the complete RE-1b (Figure 5b, lane 7) , indicating that the sequence indicated as the potential OCT-1/OCT-2 site is a bona ®de site for binding by the OCT family of transcription factors. It did not interfere with binding of band B, providing support for our hypothesis that another transcription factor(s) binds to a sequence outside the OCT-1/OCT-2 site. Oligonucleotide #5 lacked the last nucleotide of the potential OCT-1/OCT-2 site. This nucleotide is probably crucial for transcription factor binding, as oligonucleotide #5 failed to compete for protein binding represented by the two bands, B and C; however, it competed for protein binding represented by OCT-1, band A (Figure 5b, lane 9) . Thus, in RE-1b, the OCT-1/OCT-2 element is sucient for binding by OCT-1 or the protein that forms complex C, and the most 3' nucleotide`T' is necessary for the formation of complexes B and C.
Discussion
There is accumulating evidence that the extracellular matrix plays a major role in regulating cell proliferation, migration, and invasion (Pijuan-Thompson et al., 1999; Gladson, 1999; Gladson et al., 2000) . Based on the absence of most adhesive glycoproteins in the brain neuropil and in the malignant astrocytoma extracellular matrix (Pijuan-Thompson et al, 1999; Gladson, 1999) , we hypothesized that malignant astrocytoma cells must synthesize one or more new matrix or cell attachment proteins in order to attach and migrate. The evidence to date indicates that malignant astrocytoma cells synthesize OPN and vitronectin (Saitoh et al., 1995; Gladson et al., 1995) . Vitronectin promotes malignant astrocytoma cell attachment and migration (Gladson et al., 1995) ; however the function of OPN in malignant astrocytoma tumors is not clear. In other cell types, OPN can also promote cell attachment and migration, as well as cytoskeletal organization, suggesting it can serve as a cell attachment protein (Liaw et al., 1995) .
Previous studies of the regulation of OPN expression have pointed toward transcriptional regulation as a key event in upregulation of its synthesis. These studies have suggested that a number of mechanisms, including hormonal and growth factor stimulation, oncogene activation, and tumor promoters, modulate OPN gene expression at the mRNA level (reviewed in Denhardt and Noda, 1998)). However, few studies have investigated the structure of the promoter region of the OPN gene as it relates to transcriptional regulation, and in particular transcriptional regulation in malignant cells. We have reported previously that deletion of 794 to 724 of the 5' OPN promoter region in human monocytic and B lymphoma cells resulted in a signi®cant decrease in OPN promoter activity; however, the responsible element(s) within the region was not determined (Hijiya et al., 1994) .
In this paper, we identify a DNA segment in the 794 to 724 region of the human OPN promoter that is essential for maintaining high levels of OPN expression in malignant astrocytoma cells, as well as in primary astrocytes. This element, that we designated RE-1, was ®rst de®ned by 5' deletional analysis of the human OPN promoter in U-251MG and U-87MG malignant astrocytoma cells, and in primary astrocytes. RE-1 spans approximately 71 bp, from 794 to 724, relative to the transcription initiation site. Deletion of RE-1 signi®cantly reduced basal OPN promoter activity, and this element strongly activated transcription from a heterologous TK promoter, suggesting that RE-1 behaves like a transcriptional enhancer in the OPN promoter. RE-1 is located within a region of the human OPN promoter (71 to 7250) that possesses sequence homology with the OPN promoters of mouse and pig (Hijiya et al., 1994) .
Characterization of the RE-1 element using sitedirected mutagenesis showed that it consists of two elements, RE-1a and RE-1b. Internal deletions of either RE-1a or RE-1b drastically reduced OPN promoter activity. The simultaneous deletion of RE1a and RE-1b resulted in greater reduction of the promoter activity than that caused by deleting either of the individual elements, indicating these two elements act in an additive or synergistic manner in regulating OPN promoter activity. These results suggest that RE1a and RE-1b are able to control OPN transcription independently, but may also act in concert in the regulation of the OPN promoter such that both elements are necessary for the full activity of RE-1.
Nuclear protein binding assays to the RE-1a element demonstrated that several transcription factors bind speci®cally to this sequence. Gel shift experiments showed that the RE-1a element contains binding sites for Sp1, GR, and E-box-binding factors. Two Spl bands were identi®ed based on competition experiments with a Spl oligonucleotide; this binding pattern is consistent with that described by other investigators for Spl-DNA interactions. Sp1 is a ubiquitous transcription factor with a core binding sequence, CCGCCC, that exists in the promoter/enhancer region of virtually every gene and is believed to be important for basal transcription of most genes (Stein et al., 1999) . Using a deleted version of the oligonucleotide that did not contain this putative Sp1 site, we con®rmed that the Sp1 element is indeed the site responsible for the formation of the Sp1-DNA complex. Mutations overlapping this site (755/ 762M and 763/770M) caused a greater than 70% decrease in OPN promoter activity, indicating the importance of this sequence in OPN transcription in malignant astrocytoma cells. RE-1a also contains an element resembling GRE, which is recognized by an activated glucocorticoid receptor (GR) (Yamamoto, 1985) . In competition assays we showed that an oligonucleotide containing a consensus sequence for GRE binds this element. Previous work has shown that glucocorticoids can increase OPN expression in cardiac myocytes and in microvascular endothelial cells (Singh et al., 1995) . Whether the reported increase in OPN expression in these cell types by glucocorticoids is related to a GRE element in the OPN promoter awaits further elucidation.
Within RE-1a, there are also potential binding sites for Myc and USF, collectively known as the E-boxbinding factors. However, not all Myc and USF sites are necessary for protein binding. Competition experiments using deletion mutants of the RE-1a element indicated that the two middle USF sites (denoted in Figure 5a ) are sucient for transcription factor binding, while the third USF site and the c-Myc site are not essential. Blocking assays with an anti-c-Myc antibody showed that Myc either participates in forming the DNA-protein complex, or facilitates the binding of another transcription factor(s) to this site. Further suggestion of a role for Myc in regulating OPN gene transcription comes from prior studies with quail chondrocytes which indicated that constitutive expression of the v-myc oncogene increased OPN mRNA levels (Castagnola et al., 1991) . Interestingly, several studies suggest that increased expression of Myc protein is a marker of the most malignant astrocytic tumors (Trent et al., 1986; Ehgelhard et al., 1989; Orian et al., 1992) . This is likely due to ampli®cation of the myc gene, which is reported to occur in the highest grade of malignant astrocytoma (glioblastoma) (Trent et al., 1986; Ehgelhard et al., 1989; Orian et al., 1992) . Furthermore, antisense oligonucleotides directed toward myc have been reported to signi®cantly inhibit the growth of malignant astrocytoma cells in vitro, suggesting a critical role for Myc in the proliferation of these tumors (Broaddus et al., 1997) . Other transcription factors, besides Myc and USF, could also be involved in a complex associated with this site. For example, the transactivation eect of Myc requires that it dimerize with Max, and/or Mad (Henriksson and Luscher, 1996) . Results from our DNA-protein interaction assays, as well as the mutagenesis study in which mutations of the E-box site (771/778M and 779/786M) caused a signi®cant loss of the promoter activity, provide the ®rst evidence that the E-box element to which Myc binds is crucial for OPN transcription in astrocytoma cells.
We also show that the RE-1b element within RE-1 contains a binding site for the OCT family of transcription factors. DNA-protein interaction assays and antibody blocking assays demonstrated that OCT-1 binds to RE-1b, and/or assists another transcription factor(s) in binding to the OCT site. However, as two of the three DNA-protein complexes (bands B and C in Figure 4 ) associated with the RE-1b oligonucleotide were not aected by anti-OCT-1 or anti-OCT-2 antibodies, we hypothesize that other transcription factor(s) also bind to the OCT site in RE-1b.
In summary, the results described in this report present a detailed analysis of the proximal human OPN promoter, and identify several new transcription factor binding sites in this region. Using mutagenesis analysis, we have identi®ed two elements that are necessary for OPN expression.
Materials and methods
Cell culture and transfection
The U-251MG, U-87MG and U-373MG human malignant astrocytoma cell lines were obtained from the American Type Culture Collection and maintained in an atmosphere of 5% CO 2 , at 378C in Dulbecco's-modi®ed Eagle's medium supplemented with 10% fetal bovine serum, 1 mM Lglutamine and antibiotics (penicillin and streptomycin) as described (Gladson et al., 1995) . The primary neonatal rat astrocytes used in these studies were isolated on the day of birth from rat pup cerebrums from which the meninges had been removed and were then maintained as described (Benveniste et al., 1991) . Greater than 97% of the cells were positive for glial ®brillary acidic protein, and contaminating microglia, as detected by staining for non-speci®c esterase, represented less than 2% of the cells (Benveniste et al., 1991) . For transfection assays, the cells were seeded into 6-well culture plates at *50% con¯uence and grown overnight. For each transfection, 2 mg of reporter plasmid was co-transfected with either 2 mg of carrier plasmid (pBSKS+) or 1 mg of pRL-SV40, which is a plasmid encoding the Renilla luciferase (Promega) using 8 ± 10 ml of the DMRIE-C Reagent (Life Technologies, Inc.) for 16 h. Cells were harvested 24 ± 48 h after transfection and the luciferase activities were assayed as described previously (Wang et al., 1997) . Each transfection was repeated at least twice and transfection eciency was normalized using either the total protein concentration of the cell lysate or the Renilla luciferase activity encoded by the cotransfected pRL-SV40 plasmid.
Plasmids and oligonucleotide-directed mutagenesis
The 5' deletion constructs of the human OPN promoter have been described previously (Hijiya et al., 1994) . The OPN promoters of various lengths were cloned into the ®re¯y luciferase reporter plasmid pGL2-basic (Promega). To create pGL-OPN-1206/+90, the OPN promoter was released from the original plasmid by either SacI and BamHI, or BamHI and HindIII, double digestion. The resultant 1 kb and 0.3 kb fragments, respectively, were puri®ed from the agarose gel and ligated into the SacI and HindIII sites in the pGL2-basic plasmid. To create pGL-OPN7439/+90, pGL-OPN7124/ +90, pGL-OPN7114/+90, pGL-OPN794/+90, and pGL-OPN724/+90, the corresponding promoter fragments were released from the original plasmids by SacI and HindIII double digestion and ligated into the same sites in the pGL2-basic plasmid.
Mutations were introduced into the OPN promoter in the pGL-OPN7439/+90 plasmid by oligonucleotide-directed mutagenesis. pGL2-basic plasmid contains a bacteriophage replication origin and was used to generate single-stranded template DNA using the helper phage R408. Oligonucleotides containing the intended mutations in the promoter region were annealed to the promoter portion of the template DNA individually and used as primers for new strand synthesis. To aid selection of the plasmids that contained the desired mutation, a second oligonucleotide designed to mutate a nonessential restriction site in the pGL2-basic plasmid was also used for new strand synthesis. The synthesis reactions were then transformed into E. coli and plasmids containing the desired mutations were selected by restriction endonuclease analyses. The mutated promoter fragments were re-cloned into the pGL2-basic plasmid to avoid unintended mutations in the plasmid.
The sequences of the mutagenic oligonucleotide primers for each mutant promoter were as follows with the mismatch To construct the deletion mutant pD755/786, pM779/ 786 and pM755/762 were digested with EcoRI and XhoI. The resulting 5.3 kb fragment from pM779/786 and the 0.7 kb fragment from pM755/762 were puri®ed by agarose gel electrophoresis and ligated to each other in the proper orientation. The same strategies were used to construct pD722/745 (using pM738/745 and pM722/728) and pD722/786 (using pM779/786 and pM722/728).
To construct pOPN719/796-TK, oligonucleotides containing either the OPN promoter sequence between 751 and 796 or the OPN promoter sequence between 719 and 750 were synthesized. Complementary oligonucleotides were annealed and the resulting double-stranded fragments, which contain cohesive ends in the proper orientation, were ligated to each other. The resulting DNA fragment contains the wild-type OPN promoter sequence between 719 and 796 and has a BamHI restriction site at the 5' end and a XhoI restriction site at the 3' end. This fragment was ligated into the same sites in the pT81Luc plasmid (ATCC) in the proper orientation.
Nuclear extract preparation
The method used for preparation of the nuclear extracts was that described by Andrews and Faller (1991) . Brie¯y, monolayers of U-251MG cells were washed with PBS and harvested by scraping into cold PBS. The cell pellet obtained by centrifugation was resuspended in buer containing 10 mM HEPES, 1.5 mM MgCl 2 , 10 mM KCl, 1 mM DTT and 0.2 mM PMSF, vortexed brie¯y, and the nuclei pelleted by centrifugation. Nuclear proteins were extracted using high salt buer containing 20 mM HEPES, 25% glycerol, 400 mM NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 1 mM DTT, and 0.2 mM PMSF. Insoluble material was removed by centrifugation in a microcentrifuge at 14 000 r.p.m., and the supernatant containing the extracted nuclear proteins was stored at 7708C until use.
Gel mobility shift assay
Gel mobility shift assays were performed as described previously (Wang et al., 1997) . Double-stranded oligonucleotide substrates with 5' overhangs were labeled with [a-32 P]dCTP using the Klenow fragment of DNA polymerase I. The binding reactions were carried out at room temperature for 20 min in a total volume of 35 ± 40 ml containing 50 000 ± 80 000 c.p.m. (0.02 pmol) of probes, the indicated amount of protein, 20 mM HEPES (pH 7.9), 50 mM KCl, 1 mM MgCl 2 , 10% glycerol, 1 mM DTT, 0.1 mg/ml BSA, 1 mg poly(dI-dC), and, as indicated, various amounts of the unlabeled competitor oligonucleotides. The concentration of the poly (dI : dC) was optimized; concentrations greater than a 100-fold excess decreased speci®c binding. The reactions were resolved on a 6% nondenaturing acrylamide gel in 0.5X TBE buer, under the conditions described previously (Wang et al., 1997) . For antibody supershift assays, 0.5 ± 2 ng of the antibody was also included in the reaction.
The oligonucleotides used in gel mobility shift assays were as follows (only the top strands are shown): OPN751/796, 5'-GATCC AGTGGC AGAAAACCT CATGACACAATCT-CTCCGCCTCCCTGTGTT-3'; OPN719/750, 5'-GGTGG-AGGATGTCTGCAGCAGCATTTAAATTC-3'. Competitor oligonucleotides containing consensus binding sites for Sp1 and OCT-1 (OCT-2) were obtained from Promega. USF-1, myc, and GRE consensus oligonucleotides were purchased from Santa Cruz Biotechnology. The E-box oligonucleotide was a gift from Dr Jerey Kudlow (University of Alabama at Birmingham).
